Menu
← Oncology Approval Tracker
FDA DECISION ·
Libtayo
cemiplimab-rwlc · Regeneron Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As adjuvant therapy for adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
LAMPGEN ANALYSIS
Why it matters
The approval moves PD-1 treatment into the post-surgery and post-radiation setting for high-risk cutaneous disease.
What research teams should watch
Build a referral path from surgery and radiation that captures pathology risk features and treatment completion dates.
PRIMARY RECORDS